Published in J Rheumatol on December 01, 1994
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis (2003) 2.03
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet (2015) 1.83
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis (2001) 1.77
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis (2011) 1.68
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther (2005) 1.61
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis (2008) 1.49
Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis (2006) 1.47
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46
Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center. Rheumatol Int (2011) 1.40
Performance of response scales of activity and functional measures of ankylosing spondylitis: numerical rating scale versus visual analog scale. Rheumatol Int (2013) 1.39
Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis (2001) 1.38
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis (2005) 1.35
A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int (2004) 1.32
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis (2003) 1.31
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis (2005) 1.29
Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis. Arthritis Res (2001) 1.26
Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum (2005) 1.26
Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 1.26
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther (2011) 1.24
Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis (2004) 1.24
Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis (2005) 1.21
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis (2011) 1.21
Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol (2006) 1.14
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis (2007) 1.14
Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther (2012) 1.13
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis (2006) 1.11
Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res Ther (2003) 1.11
A sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis. Ann Rheum Dis (2006) 1.09
Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis (2002) 1.09
Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis (2005) 1.09
Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis (2003) 1.08
Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. Arthritis Res Ther (2009) 1.08
Symptomatic improvement in function and disease activity in a patient with ankylosing spondylitis utilizing a course of chiropractic therapy: a prospective case study. J Can Chiropr Assoc (2005) 1.07
Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int (2005) 1.07
Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. Clin Rheumatol (2016) 1.07
Restrictive pulmonary function is more prevalent in patients with ankylosing spondylitis than in matched population controls and is associated with impaired spinal mobility: a comparative study. Arthritis Res Ther (2012) 1.06
Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol (2005) 1.05
Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis (2005) 1.05
A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol (2015) 1.04
Monitoring ankylosing spondylitis therapy by dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. Skeletal Radiol (2007) 1.04
The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity. Rheumatol Int (2004) 1.04
Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. Clin Rheumatol (2006) 1.03
Assessment of enthesitis in ankylosing spondylitis by power Doppler ultrasonography. Skeletal Radiol (2006) 1.03
Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord (2012) 1.02
The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int (2010) 1.02
Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol (2007) 1.02
Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2009) 1.01
Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis (2014) 1.00
The Turkish version of the Bath Ankylosing Spondylitis Functional Index: reliability and validity. Clin Rheumatol (2004) 1.00
Adaptation of the Bath Ankylosing Spondylitis Functional Index to the Turkish population, its reliability and validity: functional assessment in AS. Clin Rheumatol (2004) 1.00
Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 0.99
Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol (2010) 0.99
Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol (2010) 0.97
Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol (2004) 0.97
Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes--an Indian perspective. Clin Rheumatol (2008) 0.97
Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis (2003) 0.97
High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection. Arthritis Res Ther (2013) 0.97
Fibromyalgia in women with ankylosing spondylitis. Rheumatol Int (2007) 0.97
Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study. Arthritis Res Ther (2012) 0.97
The relationship between severity and extent of spinal involvement and spinal mobility and physical functioning in patients with ankylosing spondylitis. Clin Rheumatol (2006) 0.97
Assessment of Sacroiliitis at Diagnosis of Juvenile Spondyloarthritis by Radiography, Magnetic Resonance Imaging, and Clinical Examination. Arthritis Care Res (Hoboken) (2016) 0.96
How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. Clin Rheumatol (2014) 0.95
Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions. Clin Rheumatol (2011) 0.95
Ankylosing spondylitis. Wien Med Wochenschr (2010) 0.95
The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int (2009) 0.94
Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol (2010) 0.94
Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int (2004) 0.94
Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int (2010) 0.94
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis (2014) 0.94
Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis (2011) 0.93
Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int (2008) 0.93
Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction. Arthritis Rheum (2009) 0.93
Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm (2014) 0.93
Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. BMC Musculoskelet Disord (2008) 0.93
Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis (2002) 0.93
Relationship between cervical sagittal alignment and quality of life in ankylosing spondylitis. Eur Spine J (2014) 0.93
Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum (2008) 0.93
Effect of HLA-B and HLA-DR genes on susceptibility to and severity of spondyloarthropathies in Mexican patients. Ann Rheum Dis (2002) 0.93
Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol (2012) 0.92
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence (2013) 0.92
Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT. Ann Rheum Dis (2013) 0.92
Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis (2004) 0.92
Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol (2007) 0.92
Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int (2011) 0.92
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis (2005) 0.91
Registry of the clinical characteristics of spondyloarthritis in a cohort of Egyptian population. Rheumatol Int (2011) 0.91
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol (1994) 11.17
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum (1997) 4.14
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol (1994) 4.00
Yeast PKA represses Msn2p/Msn4p-dependent gene expression to regulate growth, stress response and glycogen accumulation. EMBO J (1998) 3.79
SOK2 may regulate cyclic AMP-dependent protein kinase-stimulated growth and pseudohyphal development by repressing transcription. Mol Cell Biol (1995) 2.97
A comparison of standardized and narrative letters of recommendation. Acad Emerg Med (1998) 2.96
Isolation and characterization of chain-terminating nonsense mutations in a porin regulator gene, envZ. J Bacteriol (1983) 2.61
EnvZ functions through OmpR to control porin gene expression in Escherichia coli K-12. J Bacteriol (1988) 2.20
Isolation and characterization of delta ompB strains of Escherichia coli by a general method based on gene fusions. J Bacteriol (1985) 1.99
Rheumatology telephone helplines: an activity analysis. South and West of England Rheumatology Consortium. Rheumatology (Oxford) (2000) 1.96
cis-acting sites required for osmoregulation of ompF expression in Escherichia coli K-12. J Bacteriol (1986) 1.90
HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis (1996) 1.79
Sports doctors' resuscitation skills under examination: do they take it seriously? Br J Sports Med (2001) 1.76
A homolog of mammalian, voltage-gated calcium channels mediates yeast pheromone-stimulated Ca2+ uptake and exacerbates the cdc1(Ts) growth defect. Mol Cell Biol (1997) 1.73
The BST1 gene of Saccharomyces cerevisiae is the sphingosine-1-phosphate lyase. J Biol Chem (1997) 1.69
GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. Am J Med Genet (1999) 1.59
Fatigue in ankylosing spondylitis--why is it ignored? J Rheumatol (1993) 1.55
Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Health Technol Assess (1998) 1.54
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) (1999) 1.51
A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) J Rheumatol (1995) 1.49
Casein kinase I-like protein kinases encoded by YCK1 and YCK2 are required for yeast morphogenesis. Mol Cell Biol (1993) 1.49
Isolation of mutations in the alpha operon of Escherichia coli that suppress the transcriptional defect conferred by a mutation in the porin regulatory gene envZ. J Bacteriol (1987) 1.44
Ceramide-mediated growth inhibition and CAPP are conserved in Saccharomyces cerevisiae. J Biol Chem (1993) 1.43
A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum (1998) 1.41
Mutations that define the promoter of ompF, a gene specifying a major outer membrane porin protein. J Bacteriol (1985) 1.38
SMS1, a high-copy suppressor of the yeast mas6 mutant, encodes an essential inner membrane protein required for mitochondrial protein import. Mol Biol Cell (1994) 1.36
Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med (1987) 1.25
Suppression of a yeast cyclic AMP-dependent protein kinase defect by overexpression of SOK1, a yeast gene exhibiting sequence similarity to a developmentally regulated mouse gene. Mol Cell Biol (1994) 1.16
The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. J Periodontol (1998) 1.16
The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis Rheum (1998) 1.14
Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. J Urol (2001) 1.12
Evidence-based medicine, utilities, and quality of life. Curr Opin Ophthalmol (1999) 1.09
The Yak1 protein kinase of Saccharomyces cerevisiae moderates thermotolerance and inhibits growth by an Sch9 protein kinase-independent mechanism. Genetics (1994) 1.07
Utilisation of locally delivered doxycycline in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 treatment approaches. J Clin Periodontol (2001) 1.07
Cdc1 and the vacuole coordinately regulate Mn2+ homeostasis in the yeast Saccharomyces cerevisiae. Genetics (1998) 1.07
Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. J Periodontol (1997) 1.04
Socioeconomic status in ankylosing spondylitis: relationship between occupation and disease activity. J Rheumatol (1997) 1.04
Familial versus sporadic ankylosing spondylitis. Two different diseases? Arthritis Rheum (1993) 1.03
Evidence-based medicine and cost-effectiveness. J Health Care Finance (1999) 1.03
The effects of sustained release doxycycline on the anaerobic flora and antibiotic-resistant patterns in subgingival plaque and saliva. J Periodontol (2000) 0.99
Isolation of Escherichia coli mutants (cpdB) deficient in periplasmic 2':3'-cyclic phosphodiesterase and genetic mapping of the cpdB locus. J Gen Microbiol (1980) 0.97
Bath Ankylosing Spondylitis Functional Index. Br J Rheumatol (1995) 0.92
Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis (1994) 0.92
Cdc1 is required for growth and Mn2+ regulation in Saccharomyces cerevisiae. Genetics (1998) 0.92
Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. I. Study design, procedures, and management. J Periodontol (1997) 0.92
Susceptibility to ankylosing spondylitis. Rheumatology (Oxford) (2000) 0.92
Diagnostic predictability of scores of plaque, bleeding, suppuration and probing depth for probing attachment loss. 3 1/2 years of observation following initial periodontal therapy. J Clin Periodontol (1990) 0.91
Transfer of RP4::Mu to Salmonella typhimurium. J Gen Microbiol (1981) 0.91
Relative effects of plaque control and instrumentation on the clinical parameters of human periodontal disease. J Clin Periodontol (1983) 0.91
Glycine-based oral rehydration solution: reassessment of safety and efficacy. J Pediatr (1986) 0.88
Antimicrobial irrigation of deep pockets to supplement oral hygiene instruction and root debridement. I. Bi-weekly irrigation. J Clin Periodontol (1985) 0.88
A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol (1990) 0.87
Bleeding on probing and probing depth as indicators of the response to plaque control and root debridement. J Clin Periodontol (1987) 0.87
Analysis of the MHC class II encoded components of the HLA class I antigen processing pathway in ankylosing spondylitis. Ann Rheum Dis (1994) 0.87
The effect of plaque control and root debridement in molar teeth. J Clin Periodontol (1987) 0.86
Effects of long-term administration of pituitary-derived bovine growth hormone and estradiol on growth in steers. J Anim Sci (1990) 0.86
Effects of smoking on local delivery of controlled-release doxycycline as compared to scaling and root planing. J Clin Periodontol (1999) 0.86
Diarrhoeal diseases in the White Mountain Apaches: epidemiologic studies. J Diarrhoeal Dis Res (1995) 0.85
Oral rehydration therapy for acute diarrhea in ambulatory children in the United States: a double-blind comparison of four different solutions. Pediatrics (1985) 0.85
Treatment of periodontal furcation defects. (II). Bone regeneration in mandibular class II defects. J Clin Periodontol (1988) 0.85
The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert Opin Investig Drugs (1998) 0.85
Continuous cardiac output catheters: delay in in vitro response time after controlled flow changes. Anesthesiology (1998) 0.84
Periodontal regeneration in naturally occurring Class II furcation defects in beagle dogs after guided tissue regeneration with bioabsorbable barriers. J Periodontol (1997) 0.84
Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity. J Rheumatol (1999) 0.84
Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis. J Rheumatol (1991) 0.83
Detection and functional characterization of p180, a novel cell cycle regulated yeast transcription factor that binds retinoblastoma control elements. J Biol Chem (1997) 0.83
Juvenile onset ankylosing spondylitis--more girls than we thought? J Rheumatol (1997) 0.83
A DNA primer/probe system for the rapid and sensitive detection of Mycobacterium tuberculosis-complex pathogens. J Appl Bacteriol (1991) 0.82
cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi. Mol Gen Genet (1996) 0.82
The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs. Int J Radiat Oncol Biol Phys (1990) 0.81
Estrogenic and DNA-damaging activity of Red No. 3 in human breast cancer cells. Environ Health Perspect (1997) 0.81
Histologic probe position in treated and untreated human periodontal tissues. J Clin Periodontol (1982) 0.81
Guided tissue regeneration in human furcation defects after using a biodegradable barrier: a multi-center feasibility study. J Periodontol (1995) 0.80
Healing after treatment of periodontal intraosseous defects. VI. Factors influencing the healing response. J Clin Periodontol (1985) 0.80
Which patients with ankylosing spondylitis derive most benefit from an inpatient management program? J Rheumatol (1997) 0.80
Biodegradation and biocompatibility of a guided tissue regeneration barrier membrane formed from a liquid polymer material. J Biomed Mater Res (1998) 0.79
Preliminary in vivo studies on the osteogenic potential of bone morphogenetic proteins delivered from an absorbable puttylike polymer matrix. J Biomed Mater Res (2000) 0.79
Effect of transforming growth factor-beta 1 on proliferation and induction of hemoglobin accumulation in K-562 cells. Blood (1989) 0.79
Antimicrobial irrigation of deep pockets to supplement non-surgical periodontal therapy. II. Daily irrigation. J Clin Periodontol (1985) 0.79
Retrospective analysis of 376 irradiated patients with ankylosing spondylitis and nonirradiated controls. J Rheumatol (1989) 0.79
Repair following treatment of circumferential periodontal defects in dogs with collagen and expanded polytetrafluoroethylene barrier membranes. J Periodontol (1996) 0.78
Periodontal regeneration: a review of flap management. Periodontol 2000 (1993) 0.78
Treatment of periodontal furcation defects. Coronally positioned flap with or without citric acid root conditioning in class II defects. J Clin Periodontol (1993) 0.77
2 multi-center trials assessing the clinical efficacy of 5% sanguinarine in a biodegradable drug delivery system. J Clin Periodontol (1996) 0.77
Healing after treatment of periodontal intraosseous defects. III. Effect of osseous grafting and citric acid conditioning. J Clin Periodontol (1985) 0.77
New connective tissue attachment in beagles with advanced natural periodontitis. J Periodontal Res (1983) 0.77
The role of germline polymorphisms in the T-cell receptor in susceptibility to ankylosing spondylitis. Br J Rheumatol (1998) 0.77
Periodontal regeneration of a class II furcation defect utilizing a bioabsorbable barrier in a human. A case study with histology. J Periodontol (2001) 0.77
New Zealand general practice nurses' roles in mental health care. Int Nurs Rev (2011) 0.76
Diarrhoeal diseases in the White Mountain Apaches: clinical studies. J Diarrhoeal Dis Res (1995) 0.76
Root resorption following periodontal flap procedures in monkeys. J Periodontal Res (1985) 0.76
HLA B27, the arthritogenic peptide, and the effector T cell. Lancet (1993) 0.75
Chronic groin pain in an athlete: an unusual presentation. Br J Sports Med (1998) 0.75
Maternal age and the risk of developing ankylosing spondylitis. Ann Rheum Dis (1997) 0.75